SCHEMBL5136228

SCHEMBL5136228

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(C(C)(C)C)cc1)CC1CCCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.42
TSHR P16473 5/20 0.35
ALDH1A1 P00352 5/20 0.35
CYP3A4 P08684 5/20 0.35
KDM4E B2RXH2 4/20 0.35
HSD17B10 Q99714 4/20 0.35
HPGD P15428 3/20 0.35
BCHE P06276 2/20 0.33
HDAC1 Q13547 1/20 0.33
CRHR1 P34998 1/20 0.33
ALOX15 P16050 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA2B P29275 1/20 0.33
ADORA1 P30542 1/20 0.33
CYP19A1 P11511 1/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
GAA P10253 1/20 0.33
CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134723 0.93 C5AR1 (0.42) C5AR1TSHRALDH1A1CYP3A4KDM4E
SCHEMBL5135713 0.92 C5AR1 (0.44) C5AR1TSHRALDH1A1CYP3A4KDM4E
SCHEMBL5137864 0.92 C5AR1 (0.44) C5AR1TSHRALDH1A1CYP3A4KDM4E
SCHEMBL5134910 0.91 C5AR1 (0.44) C5AR1TSHRALDH1A1CYP3A4KDM4E
SCHEMBL5134999 0.91 C5AR1 (0.44) C5AR1TSHRALDH1A1CYP3A4KDM4E
SCHEMBL5135678 0.90 C5AR1 (0.43) C5AR1TSHRALDH1A1CYP3A4KDM4E
SCHEMBL5135753 0.90 C5AR1 (0.43) C5AR1TSHRALDH1A1CYP3A4KDM4E
SCHEMBL5137114 0.90 C5AR1 (0.43) C5AR1TSHRALDH1A1CYP3A4KDM4E
SCHEMBL5134718 0.90 C5AR1 (0.43) C5AR1TSHRALDH1A1CYP3A4KDM4E
SCHEMBL4764006 0.89 ABCC1 (0.43) C5AR1TSHRALDH1A1CYP3A4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed